The two faces of L-DOPA: benefits and adverse side effects in the treatment of Encephalitis lethargica, Parkinson's disease, multiple sclerosis and amyotrophic lateral sclerosis.
D000690:Amyotrophic Lateral Sclerosis / Q000188:drug therapy*; D000975:Antioxidants / Q000627:therapeutic use*; D000978:Antiparkinson Agents / Q000009:adverse effects / Q000627:therapeutic use; D015259:Dopamine Agents / Q000009:adverse effects / Q000627:therapeutic use; D004409:Dyskinesia, Drug-Induced / Q000209:etiology; D005767:Gastrointestinal Diseases / Q000139:chemically induced; D006212:Hallucinations / Q000139:chemically induced; D006801:Humans; D007980:Levodopa / Q000009:adverse effects* / Q000627:therapeutic use*; D009103:Multiple Sclerosis / Q000188:drug therapy*; D018384:Oxidative Stress / Q000187:drug effects; D010300:Parkinson Disease / Q000188:drug therapy*; D010301:Parkinson Disease, Postencephalitic / Q000188:drug therapy; D011605:Psychoses, Substance-Induced / Q000209:etiology; D007319:Sleep Initiation and Maintenance Disorders / Q000139:chemically induced; D014803:Vitamin B Complex / Q000627:therapeutic use*
D000975:Antioxidants; D000978:Antiparkinson Agents; D015259:Dopamine Agents; D014803:Vitamin B Complex; D007980:Levodopa